Serological Biomarkers of the Extracellular Matrix Reflecting Fibroblast Activity and Endothelial Damage are Elevated in Patients at Risk of MASH With Significant Liver Stiffness

Publication Authors:

Diana Julie Leeming1, Thomas Wiggers1;2, David Provenghi3, Peder Frederiksen1, Heidi Guthrie3, Marcus Hompesch3, Morten Karsdal1

1Nordic Bioscience, Herlev, Denmark, 2University of Copenhagen, Department of BiomedicalSciences, Copenhagen, Denmark, 3Prosciento, Inc., Chula Vista, United States

About

A co-authored poster by ProSciento and Nordic Bioscience was presented at the SLD EASL Summit by Diana Julie Leeming, mMBA, MSc, PhD, Senior Director, Hepatic & Pulmonary Research at Nordic Bioscience. The poster explores non-invasive biomarkers for hepatic fibrosis in patients at risk of metabolic dysfunction-associated steatohepatitis (MASH).

MASH-related fibrosis results from excessive collagen deposition, increasing liver stiffness. Our research investigates how PRO-C3, PRO-C4, and PRO-C6 biomarkers—which assess fibroblast activation and endothelial damage—correlate with liver stiffness in patients at risk due to obesity and type 2 diabetes. View abstract on page 133.

VIEW
Serological Biomarkers of the Extracellular Matrix Reflecting Fibroblast Activity and Endothelial Damage are Elevated in Patients at Risk of MASH With Significant Liver Stiffness thumbnail